Tandem Diabetes Care Inc (TNDM) stock
Close on Nov 17, 2026Market cap $1.19BP/E –Yield –
Earnings
Tandem Diabetes Care's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Tandem Diabetes Care's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 18, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026after the close | $283.70M | +13.8% | -$0.10 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026during market hours | $254.60M | +5.8% | -$0.31 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026during market hours | $247.20M | +5.5% | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 19, 2026during market hours | $290.40M | +2.8% | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025during market hours | $249.30M | +2.2% | -$0.31 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 6, 2025during market hours | $240.70M | +8.5% | -$0.78 | Release |
| Q1 FY2025ended Mar 31, 2025 | Apr 30, 2025during market hours | $234.40M | +22.3% | -$1.97 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 26, 2025during market hours | $282.60M | +43.6% | $0.01 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 6, 2024during market hours | $244.00M | +31.4% | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 1, 2024during market hours | $221.90M | +13.3% | -$0.47 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 2, 2024during market hours | $191.70M | +13.2% | -$0.65 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 21, 2024during market hours | $196.80M | -10.8% | -$0.46 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 1, 2023during market hours | $185.62M | -9.2% | -$0.51 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023during market hours | $195.92M | -2.2% | -$0.55 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 3, 2023during market hours | $169.38M | -3.7% | -$1.92 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 22, 2023during market hours | $220.50M | +5.0% | -$0.25 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 2, 2022during market hours | $204.50M | +13.9% | -$0.76 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 3, 2022during market hours | $200.30M | – | -$0.24 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 4, 2022during market hours | $175.90M | – | -$0.23 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 22, 2022during market hours | $210.00M | – | $0.16 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 3, 2021during market hours | $179.60M | – | $0.09 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 4, 2021during market hours | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 5, 2021during market hours | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 24, 2021during market hours | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Tandem Diabetes Care's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Sales | FY2026 | $1.07B – $1.09B | – | New | Nov 5, 2026 |
| Sales | FY2026 | $1.07B – $1.09B | $1.07B – $1.09B | Raised | Aug 6, 2026 |
| SalesGAAP | FY2026 | $730.00M – $745.00M | – | Lowered | Feb 19, 2026 |
| Gross marginGAAP | FY2026 | 56% – 57% | – | New | Nov 5, 2026 |
| Gross margin | FY2026 | 56% – 57% | 56% – 57% | Reaffirmed | Aug 6, 2026 |
| Gross marginGAAP | FY2026 | 56% – 57% | – | New | Feb 19, 2026 |
| Adjusted EBITDA marginnon-GAAP | FY2026 | 5% – 6% | – | New | Nov 5, 2026 |
| Adjusted EBITDA marginnon-GAAP | FY2026 | 5% – 6% | – | New | Feb 19, 2026 |
| Adjusted EBITDA marginnon-GAAP | FY2026 | 5% – 6% | 5% – 6% | Reaffirmed | Aug 6, 2026 |
| depreciation and amortization expense | FY2026 | $20.00M | $20.00M | Lowered | Aug 6, 2026 |
| Non-cash charges included in cost of goods sold and operating expenses | FY2026 | $85.00M | $100.00M | Raised | Aug 6, 2026 |
| non-cash, stock-based compensation expense | FY2026 | $65.00M | $80.00M | Lowered | Aug 6, 2026 |
Guidance vs results
The last range Tandem Diabetes Care gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $1.00B | $1.01BΣ4Q | Above range |
| Q1 FY2025 | Revenue | $219.00M – $224.00M | $234.40M | Above range |
| Q3 FY2024 | Revenue | $222.00M – $225.00M | $244.00M | Above range |
| Q2 FY2024 | Revenue | $205.00M | $221.90M | Above range |
| Q1 FY2024 | Revenue | $175.00M | $191.70M | Above range |
| Q3 FY2023 | Revenue | $190.00M | $185.62M | Below range |
Guidance history
Every forecast Tandem Diabetes Care put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 5, 2026 | Adjusted EBITDA margin | FY2026 | 5% – 6% | New |
| Nov 5, 2026 | Gross margin | FY2026 | 56% – 57% | New |
| Nov 5, 2026 | Sales | FY2026 | $1.07B – $1.09B | New |
| Aug 6, 2026 | Gross margin | FY2026 | 56% – 57% | Reaffirmed |
| Aug 6, 2026 | Adjusted EBITDA margin | FY2026 | 5% – 6% | Reaffirmed |
| Aug 6, 2026 | Non-cash charges included in cost of goods sold and operating expenses | FY2026 | $85.00M | Raised |
| Aug 6, 2026 | non-cash, stock-based compensation expense | FY2026 | $65.00M | Lowered |
| Aug 6, 2026 | depreciation and amortization expense | FY2026 | $20.00M | Lowered |
| Aug 6, 2026 | Sales | FY2026 | $1.07B – $1.09B | Raised |
| Aug 6, 2026 | U.S. sales | FY2026 | $730.00M – $745.00M | Lowered |
| Aug 6, 2026 | International sales | FY2026 | $335.00M – $340.00M | Lowered |
| May 7, 2026 | Gross margin | FY2026 | 56% – 57% | New |
| May 7, 2026 | Adjusted EBITDA margin | FY2026 | 5% – 6% | New |
| May 7, 2026 | Non-cash charges included in cost of goods sold and operating expenses | FY2026 | $100.00M | Raised |
| May 7, 2026 | non-cash, stock-based compensation expense | FY2026 | $80.00M | Lowered |
| May 7, 2026 | depreciation and amortization expense | FY2026 | $20.00M | Lowered |
| May 7, 2026 | Sales | FY2026 | $1.07B – $1.09B | New |
| May 7, 2026 | United States sales | FY2026 | $730.00M – $745.00M | Lowered |
| May 7, 2026 | International sales | FY2026 | $335.00M – $340.00M | Lowered |
| Feb 19, 2026 | Adjusted EBITDA margin | FY2026 | 5% – 6% | New |
| Feb 19, 2026 | Gross margin | FY2026 | 56% – 57% | New |
| Feb 19, 2026 | non-cash, stock-based compensation expense | FY2026 | $80.00M | Lowered |
| Feb 19, 2026 | Non-cash charges included in cost of goods sold and operating expenses | FY2026 | $100.00M | New |
| Feb 19, 2026 | depreciation and amortization expense | FY2026 | $20.00M | Lowered |
| Feb 19, 2026 | Sales | FY2026 | $730.00M – $745.00M | Lowered |
| Feb 19, 2026 | Sales | FY2026 | $1.07B – $1.09B | New |
| Feb 19, 2026 | Sales | FY2026 | $335.00M – $340.00M | Lowered |
| Nov 6, 2025 | Adjusted EBITDA margin | FY2025 | -5% | New |
| Nov 6, 2025 | Gross margin | FY2025 | 53% – 54% | New |
| Nov 6, 2025 | Sales | FY2025 | $1.00B | New |
| Aug 6, 2025 | Gross margin | FY2025 | 53% – 54% | New |
| Aug 6, 2025 | Adjusted EBITDA margin | FY2025 | -5% | Lowered |
| Aug 6, 2025 | Non-cash charges included in cost of goods sold and operating expenses | FY2025 | $115.00M | Raised |
| Aug 6, 2025 | non-cash, stock-based compensation expense | FY2025 | $95.00M | Lowered |
| Aug 6, 2025 | depreciation and amortization expense | FY2025 | $20.00M | Lowered |
| Aug 6, 2025 | Sales | FY2025 | $1.00B | New |
| Aug 6, 2025 | Sales in the United States | FY2025 | $700.00M | Lowered |
| Aug 6, 2025 | Sales outside the United States | FY2025 | $300.00M | Lowered |
| Apr 30, 2025 | Adjusted EBITDA margin | FY2025 | 3% | New |
| Apr 30, 2025 | Gross margin | FY2025 | 54% | Reaffirmed |
| Apr 30, 2025 | Non-cash charges included in cost of goods sold and operating expenses | FY2025 | $115.00M | Raised |
| Apr 30, 2025 | non-cash, stock-based compensation expense | FY2025 | $95.00M | Lowered |
| Apr 30, 2025 | depreciation and amortization expense | FY2025 | $20.00M | Lowered |
| Apr 30, 2025 | Sales | FY2025 | $997.00M – $1.01M | Lowered |
| Apr 30, 2025 | Sales in the United States | FY2025 | $725.00M – $730.00M | Raised |
| Apr 30, 2025 | Sales outside the United States | FY2025 | $272.00M – $277.00M | Lowered |
| Feb 26, 2025 | Gross margin | Q1 FY2025 | 51% | New |
| Feb 26, 2025 | Gross margin | FY2025 | 54% | New |
| Feb 26, 2025 | Adjusted EBITDA margin | Q1 FY2025 | -6% | New |
| Feb 26, 2025 | Sales in the United States | Q1 FY2025 | $144.00M – $147.00M | New |
| Feb 26, 2025 | Sales outside the United States | Q1 FY2025 | $75.00M – $77.00M | Lowered |
| Feb 26, 2025 | Adjusted EBITDA margin | FY2025 | 3% | New |
| Feb 26, 2025 | Non-cash charges included in cost of goods sold and operating expenses | FY2025 | $115.00M | New |
| Feb 26, 2025 | non-cash, stock-based compensation expense | FY2025 | $95.00M | Lowered |
| Feb 26, 2025 | depreciation and amortization expense | FY2025 | $20.00M | Lowered |
| Feb 26, 2025 | Sales in the United States | FY2025 | $725.00M – $730.00M | New |
| Feb 26, 2025 | Sales outside the United States | FY2025 | $272.00M – $277.00M | Lowered |
| Feb 26, 2025 | Sales | Q1 FY2025 | $219.00M – $224.00M | New |
| Feb 26, 2025 | Sales | FY2025 | $997.00B – $1.01B | New |
| Nov 6, 2024 | Non-GAAP gross margin | FY2024 | 51% | Reaffirmed |
| Nov 6, 2024 | Non-GAAP sales | FY2024 | $903.00M – $910.00M | Raised |
| Aug 1, 2024 | Non-GAAP gross margin | Q3 FY2024 | 51% | New |
| Aug 1, 2024 | Non-GAAP gross margin | FY2024 | 51% | Reaffirmed |
| Aug 1, 2024 | Non-GAAP sales | Q3 FY2024 | $222.00M – $225.00M | New |
| Aug 1, 2024 | Non-GAAP sales | FY2024 | $885.00M – $892.00M | Raised |
| May 2, 2024 | Adjusted EBITDA margin | Q2 FY2024 | -5% | New |
| May 2, 2024 | Non-GAAP gross margin | Q2 FY2024 | 50% | New |
| May 2, 2024 | Non-GAAP gross margin | FY2024 | 51% | Reaffirmed |
| May 2, 2024 | Non-GAAP sales | Q2 FY2024 | $205.00M | New |
| May 2, 2024 | Non-GAAP sales | FY2024 | $868.00M | Raised |
| Feb 21, 2024 | Adjusted EBITDA margin | Q1 FY2024 | -15% | New |
| Feb 21, 2024 | Non-GAAP gross margin | Q1 FY2024 | 48% | New |
| Feb 21, 2024 | Non-GAAP gross margin | FY2024 | 51% | New |
| Feb 21, 2024 | Non-GAAP sales | Q1 FY2024 | $175.00M | New |
| Feb 21, 2024 | Non-GAAP sales | FY2024 | $850.00M | New |
| Nov 1, 2023 | Non-GAAP gross margin | FY2023 | 51% | Reaffirmed |
| Nov 1, 2023 | Non-cash charges included in cost of goods sold and operating expenses | FY2023 | $110.00M | Lowered |
| Nov 1, 2023 | Non-GAAP sales | FY2023 | $765.00M | Lowered |
| Aug 3, 2023 | Non-GAAP gross margin | FY2023 | 51% | Lowered |
| Aug 3, 2023 | sales | Q3 FY2023 | $190.00M | New |
| Aug 3, 2023 | Non-GAAP sales | FY2023 | $785.00M | Lowered |
| May 3, 2023 | Adjusted EBITDA margin | FY2023 | 5% – 6% | Reaffirmed |
| May 3, 2023 | Non-GAAP gross margin | FY2023 | 52% | Reaffirmed |
| May 3, 2023 | Non-GAAP sales | FY2023 | $885.00M – $900.00M | Reaffirmed |
| Feb 22, 2023 | Adjusted EBITDA margin | FY2023 | 5% – 6% | New |
| Feb 22, 2023 | Non-GAAP gross margin | FY2023 | 52% | New |
| Feb 22, 2023 | Non-cash charges included in cost of goods sold and operating expenses | FY2023 | $115.00M | New |
| Feb 22, 2023 | Non-GAAP sales | FY2023 | $885.00M – $900.00M | New |
| Nov 2, 2022 | Adjusted EBITDA margin* | FY2022 | 7% – 8% | Lowered |
| Nov 2, 2022 | Non-GAAP gross margin* | FY2022 | 52% | New |
| Nov 2, 2022 | Non-cash charges included in cost of goods sold and operating expenses | FY2022 | $100.00M | New |
| Nov 2, 2022 | Non-GAAP sales* | FY2022 | $800.00M – $805.00M | New |
| Aug 3, 2022 | Adjusted EBITDA | FY2022 | 11% | Lowered |
| Aug 3, 2022 | Gross margin | FY2022 | 52% – 53% | Lowered |
| Aug 3, 2022 | Sales | FY2022 | $835.00M – $845.00M | Lowered |
| May 4, 2022 | Adjusted EBITDA | FY2022 | 14% – 15% | Reaffirmed |
| May 4, 2022 | Gross margin | FY2022 | 54% | Reaffirmed |
| May 4, 2022 | Sales | FY2022 | $850.00M – $865.00M | Raised |
| Feb 22, 2022 | Adjusted EBITDA | FY2022 | 14% – 15% | New |
| Feb 22, 2022 | Gross margin | FY2022 | 54% | New |
| Feb 22, 2022 | Sales | FY2022 | $845.00M – $860.00M | New |
| Nov 3, 2021 | Adjusted EBITDA | FY2021 | 15% | New |
| Nov 3, 2021 | Gross margin | FY2021 | 54% | New |
| Nov 3, 2021 | Sales | FY2021 | $685.00M – $695.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Tandem Diabetes Care filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- News
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- News
- News
See a number that looks wrong?